The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Optimizing immunosuppressive strategies for managing immune-related adverse events in lung cancer
Umair Mahmood, BSc, MSc, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares insights on optimizing immunosuppressive strategies to manage immune-related adverse events in patients with lung cancer. He emphasizes the importance of monitoring high-dose prednisolone use, noting that doses of 60mg or lower may lead to better clinical outcomes. the need to assess the role of additional immunosuppressive agents, such as infliximab, in conjunction with corticosteroids is additionally highlighted. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
